Also known as: Pancreas Bioregulator, Pancragen Khavinson Peptide
Half-life: Short (minutes); biological effect persists via gene-expression modulation
Last reviewed: · Published:
Pancragen is a short peptide bioregulator from the Khavinson family, designed for pancreatic applications. It is reported to target both exocrine and endocrine pancreatic tissue — the digestive-enzyme-producing acinar cells and the insulin- and glucagon-producing islet cells. The compound has been used in Russian clinical settings for chronic pancreatitis and as an adjunctive support in type 2 diabetes mellitus, with the goal of improving residual β-cell function and supporting digestive-enzyme production.
Russian clinical-observational studies have reported improvements in fasting glucose, HbA1c, and digestive function in elderly study populations and in patients with chronic pancreatic insufficiency. The mechanism is presumed to involve modulation of gene expression in pancreatic cells via the broader Khavinson short-peptide bioregulator pathway.
Pancragen is sold by research-chemical vendors outside Russia. Western clinical data is essentially absent. The compound is not a substitute for proven diabetes therapies (metformin, GLP-1 agonists, insulin) and patients with diabetes should not modify their medication regimen based on Pancragen use without physician supervision.
Pancragen was developed in the 2000s as part of the Khavinson bioregulator program, with the pancreatic-targeting member of the family aimed at chronic pancreatitis, exocrine insufficiency, and type 2 diabetes contexts. The compound entered Russian clinical observational use through the 2000s and 2010s.
Russian clinical use has reported good tolerability in pancreatic-insufficiency and diabetic populations. Western safety validation is essentially absent. Diabetics using Pancragen alongside conventional diabetes medications should monitor blood glucose closely to detect any additive hypoglycemia effect, though Russian reports do not describe this as a common problem.
Dose Range
1-5 mg
Frequency
Once daily (SubQ) or sublingual
Duration
10-20 day cycles, repeated 2-3 times per year
Dosing information is for educational purposes only. Consult a healthcare professional before using any peptide.
Typical Vial Size
20 mg
Water Type
Bacteriostatic water (BAC water)
Mixing Volume
2 mL
Half-Life
Short (minutes); biological effect persists via gene-expression modulation
Molecular Weight
~400-600 Da
Store reconstituted vial refrigerated at 2-8°C. Use within 21-30 days. Sublingual or subcutaneous administration is typical.
FDA Status
Not FDA approved.
Legal Status
Unregulated research chemical outside Russia.
USA
Not approvedResearch-only
EU
Not approvedNot authorized as medicinal product
UK
Not approvedClassified as research chemical
Russia
Used in clinical practiceUsed as bioregulator in Russian endocrinology and gastroenterology
Australia
Not approvedTGA has not evaluated
Canada
Not approvedNot authorized for human use
Khavinson VK, Kuznik BI, Tarnovskaya SI, Linkova NS
Bulletin of Experimental Biology and Medicine (2015)
Foundational Khavinson-group review covering the full short-peptide bioregulator family including Pancragen.
View Study →Khavinson VK, Anisimov VN, Linkova NS, Bakhmet AA
Bulletin of Experimental Biology and Medicine (2020)
Modern Khavinson-group mechanistic review applicable to pancreatic-targeting bioregulators including Pancragen.
View Study →Khavinson VK, Kuznik BI, Linkova NS
Advances in Gerontology (2019)
Russian-group review covering peptide bioregulators (including Pancragen) in endocrinological applications, supporting the rationale for pancreatic-focused use.
View Study →Khavinson short peptide bioregulator targeting hepatocytes and liver function.
Khavinson short peptide bioregulator targeting thymus / immune cells.
Khavinson short peptide bioregulator targeting testicular tissue.
Track Pancragen and more with PinnyPeptide.
Sign Up to Track PancragenFree forever · defaults pre-filled from this article